BLFS vs. ZYXI, EDAP, AXGN, OM, INMD, SLNO, CNMD, EOLS, TNGX, and CTKB
Should you be buying BioLife Solutions stock or one of its competitors? The main competitors of BioLife Solutions include Zynex (ZYXI), Edap Tms (EDAP), AxoGen (AXGN), Outset Medical (OM), InMode (INMD), Soleno Therapeutics (SLNO), CONMED (CNMD), Evolus (EOLS), Tango Therapeutics (TNGX), and Cytek Biosciences (CTKB). These companies are all part of the "medical" sector.
BioLife Solutions (NASDAQ:BLFS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.
In the previous week, BioLife Solutions had 22 more articles in the media than Zynex. MarketBeat recorded 26 mentions for BioLife Solutions and 4 mentions for Zynex. BioLife Solutions' average media sentiment score of 0.79 beat Zynex's score of 0.78 indicating that BioLife Solutions is being referred to more favorably in the media.
BioLife Solutions received 279 more outperform votes than Zynex when rated by MarketBeat users. Likewise, 66.74% of users gave BioLife Solutions an outperform vote while only 51.16% of users gave Zynex an outperform vote.
BioLife Solutions presently has a consensus price target of $23.67, indicating a potential upside of 5.51%. Zynex has a consensus price target of $18.00, indicating a potential upside of 65.75%. Given Zynex's higher probable upside, analysts clearly believe Zynex is more favorable than BioLife Solutions.
93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 2.7% of BioLife Solutions shares are owned by insiders. Comparatively, 52.1% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
BioLife Solutions has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, Zynex has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500.
Zynex has a net margin of 4.33% compared to BioLife Solutions' net margin of -45.84%. Zynex's return on equity of 16.34% beat BioLife Solutions' return on equity.
Zynex has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
Summary
Zynex beats BioLife Solutions on 9 of the 17 factors compared between the two stocks.
Get BioLife Solutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLife Solutions Competitors List
Related Companies and Tools
